OncoSec helps 57% of non-responders to immunotherpy become responders

› Forums › General Melanoma Community › OncoSec helps 57% of non-responders to immunotherpy become responders

  • This topic is empty.
  • Post
    • December 31, 2017 at 4:25 am
    Anonymous
    Inactive

      Interesting findings: https://seekingalpha.com/article/4122712-oncosec-presses-forward-positive-melanoma-combo-study

       

      "The phase 2 results showed that the patients in the trial that took the combo therapy (ImmunoPulse IL-12 and Keytruda) achieved a 57% progression-free survival rate at 15 months. That is pretty impressive, especially when you consider the fact that these patients didn't respond at all with an anti-PD-1 alone. What's even better is the fact that 11 out of 11 or 100% of the patients had a duration of response. In addition, the median PFS has not yet been reached."

    • You must be logged in to reply to this topic.
    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

    Popular Topics